We work on some of the most complex molecules in development. Our scientists write about it, present on it, and share what they have learned, so you can move your program forward with more confidence. Drug product, nanomedicine, bioanalysis, drug substance. Written by the people who deliver these programs every day.
Live conferences and on-demand webinars where you can connect with our scientific team.
BOS Basel 2026 Join Ardena at BOS Basel 2026, taking place June 30 – July 1 in Basel, Switzerland. BOS Basel is a focused partnering event bringing together biotech and pharma decision-makers to discuss collaboration opportunities and business development across the life sciences ecosystem. Meet our delegate:To be confirmed Booth:44 (pending confirmation) We look forward […]
BIO is where the biotech world comes together — and where the most complex development conversations start. Ardena is an integrated CDMO and bioanalytical CRO built for the molecules that don’t follow the rules. Whether you’re advancing a complex formulation, a nanomedicine, an HPAPI, or a sterile injectable, book time with our team to talk […]
Ardena’s first nanomedicine symposium brings together leading scientists, clinicians, and industry experts to discuss the latest advances in nanomedicine and ADC development.
Insights and perspectives from our team on industry trends and scientific advances.
The modern pharmaceutical pipeline is rich in highly potent, highly specific New Chemical Entities (NCEs). Yet, approximately 70% to 90% of new chemical entities and up to 40% of marketed drugs fall within BCS Class II or IV, reflecting the widespread challenge of poor aqueous solubility. When a molecule crosses your desk as a “brick […]
As molecular complexity continues to increase, pharmaceutical companies are increasingly turning to AI in drug development to predict and optimize critical properties such as solubility and bioavailability. By identifying patterns in chemical data, AI can estimate parameters such as pKa and logP, as well as predict formulation-dependent effects on absorption. These capabilities allow for more […]
In the complex world of nanomedicine, staying ahead of analytical challenges is a core focus of our work at Ardena. We are looking forward to taking this conversation further at our upcoming ‘Nanomedicine & Bioconjugation Symposium 2026’ this September. As an organization, our guiding principle is “We Know Nano™,” reflecting our deep-rooted expertise in navigating […]
Real-world examples of how our expertise has helped partners advance their programs.
Poor aqueous solubility remains a formidable barrier in drug development, with approximately 90% of new chemical entities facing significant challenges in achieving effective bioavailability. To overcome these limitations, pharmaceutical developers frequently employ solubility enhancement techniques, ranging from particle size reduction to solid-state modifications and advanced formulation-based strategies. At Ardena, our approach emphasizes salt screening, lipid-based […]
A shift to a four-arm, multi-dose Phase IIa protocol introduced new requirements for dosing accuracy, traceability, and patient usability. Learn how Ardena designed a modular secondary packaging solution that integrated existing blister configurations and enabled seamless execution of the updated clinical design.
Long-acting biologics present specific challenges for immunogenicity assessment, particularly when residual drug interferes with ADA detection. In this case study, Ardena outlines how a drug-tolerant ADA assay was established for a high-dose monoclonal antibody, enabling reliable detection in samples with high circulating drug levels. Discover how targeted optimisation of a PandA-based approach delivered a robust, […]
In-depth scientific papers from our experts on emerging methods and technologies.
Nanomedicines demand tight control over particle properties, reproducibility, and scalability, yet conventional batch methods often struggle to deliver all three. In this whitepaper, Ardena’s nanomedicines experts Mark van Eldijk and Andy Bänziger explore how flow manufacturing can enable more consistent nanoparticle production, simplify scale-up, and support robust development pathways from early-stage research through GMP manufacturing. […]
The ICH has released a draft consolidated guideline (ICH Q1) that unifies the previous Q1A–Q1F series into a single global standard. This revision simplifies stability requirements, integrates lifecycle management, and expands the scope to advanced therapies and drug-device combinations. This whitepaper provides a clear overview of the key changes — from predictive tools and modeling […]
Nanomedicines are redefining pharmaceutical innovation, but their complexity demands advanced analytical solutions.In this whitepaper, Ardena explores the analytical and regulatory challenges of characterizing nanoparticle-based drug delivery systems, and how state-of-the-art techniques like AF4-MALS-DLS can provide critical insights into particle size, morphology, stability, and drug loading. Gain a deeper understanding of: – How to identify and […]
Conversations with our scientists and partners on drug development science.
Coming soon — stay tuned.
